Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Conditions:   Colorectal Carcinoma;   Endometrial Carcinoma;   Melanoma;   Neuroblastoma;   Ovarian Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Desmoid Fibromatosis;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent M alignant Solid Neoplasm;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Refractory Desmoid Fibromatosis;   Refractory Ewing Sarcoma;   Re...
Source: ClinicalTrials.gov - April 20, 2021 Category: Research Source Type: clinical trials

Quality of Life of Patients With Desmoid-type Fibromatosis
Conditions:   Desmoid Tumor;   Desmoid-type Fibromatosis Intervention:   Other: Questionnaires Sponsors:   Erasmus Medical Center;   Radboud University;   The Netherlands Cancer Institute Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 2, 2020 Category: Research Source Type: clinical trials

Observing People With Desmoid-Type Fibromatosis
Condition:   Desmoid Fibromatosis Intervention:   Diagnostic Test: Cross-sectional imaging Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2020 Category: Research Source Type: clinical trials

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Conditions:   Desmoid-Type Fibromatosis;   Recurrent Desmoid-Type Fibromatosis;   Unresectable Desmoid-Type Fibromatosis Interventions:   Drug: Nirogacestat;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2019 Category: Research Source Type: clinical trials

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Conditions:   Desmoid-Type Fibromatosis;   Recurrent Desmoid-Type Fibromatosis;   Unresectable Desmoid-Type Fibromatosis Interventions:   Drug: Nirogacestat;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   SpringWorks Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2019 Category: Research Source Type: clinical trials

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Conditions:   Desmoid-Type Fibromatosis;   Recurrent Desmoid-Type Fibromatosis;   Unresectable Desmoid-Type Fibromatosis Interventions:   Drug: Nirogacestat;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2019 Category: Research Source Type: clinical trials

Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis
Conditions:   Desmoid;   Desmoid Fibromatosis of Skin;   Desmoid Neoplasm of Chest Wall;   Desmoid Tumor Caused by Somatic Mutation;   Aggressive Fibromatoses;   Fibromatosis Desmoid;   Desmoid Fibromatosis Intervention:   Procedure: Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis Sponsor:   Rabin Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2019 Category: Research Source Type: clinical trials